Human neutrophils from peripheral blood may physically interact with platelets in several settings including hemostasis, inflammation, and a variety of vascular disorders. A role for lipoxygenase (LO)-derived products has been implicated in each of these events; therefore, we investigated the formation of lipoxins during coincubation of human neutrophils and platelets. Simultaneous addition of FMLP and thrombin to coincubations of these cells led to formation of both lipoxin A4 and lipoxin B4, which were monitored by reversed-phase high pressure liquid chromatography. Neither stimulus nor cell type alone induced the formation of these products. When leukotriene A4 (LTA4), a candidate for the transmitting signal, was added to platelets, lipoxins were formed. In cell-free 100,000 g supernatants of platelet lysates, which displayed 12-LO activity, LTA4 was also transformed to lipoxins. Platelet formation of lipoxins was inhibited by the LO inhibitor esculetin and partially sensitive to chelation of Ca2+, while neither acetylsalicylic acid nor indomethacin significantly inhibited their generation. In contrast, neutrophils did not transform LTA4 to lipoxins. Cell-free 100,000 g supernatants of neutrophil lysates converted LTA4 to LTB4. These results indicate that neutrophil-platelet interactions can lead to the formation of lipoxins from endogenous sources and provide a role for platelet 12-LO in the formation of lipoxins from LTA4.
Introduction
Lipoxygenase (LO), which are widely distributed in human tissues, transform nonesterified arachidonic acid to biologically active products that may play roles in both normal and pathophysiologic processes (1) (2) (3) . The three major LOs (5-, 15-, and 12-LO) are compartmentalized within different cell types of peripheral blood. For example, upon stimulation human platelets activate an arachidonate 12-LO (4), while human neutrophils (PMN) possess both 5-and 15-LOs (5) . Initial oxygenation of arachidonic acid (AA) via 5-LO leads to leukotrienes, which are held to play important roles in both inflammation and allergic reactions (1) (2) (3) .
Interactions between the 5-and 15-LOs can lead to the formation of lipoxins (6) . The lipoxins are a series of acyclic eicosanoids that contain a conjugated tetraene structure and three alcohol groups as characteristic features. The two main compounds of this series are positional isomers: one designated lipoxin A4 (5S,6R, 1 5S-trihydroxy-7,9, 13-trans-I1 -ciseicosatetraenoic acid) and the other lipoxin B4 (5S, 14R, 15Strihydroxy-6,10,12-trans-8-cis-eicosatetraenoic acid) (7, 8) . LXA4 and LXB4 each display profiles of activity that are distinct from those of other eicosanoids (reviewed in reference 1). Multiple pathways have been demonstrated for the biosynthesis of lipoxins (6-1 1). One route involves initial oxygenation by the 1 5-LO and formation of a 5(6)-epoxytetraene intermediate by human leukocytes to give LXA4 and LXB4 (8) .
There is increasing appreciation that platelets play significant roles in modulating immunologic responses (12, 13) . Interactions between platelets and PMNs can lead to the transcellular metabolism of eicosanoids (14) and the formation of products not generated by either cell type alone (15) . During the course of the present investigation, Edenius et al. (16) reported that mixed platelet-granulocyte suspensions stimulated with the ionophore A23187 generate LXA4 and four other lipoxins from endogenous sources of arachidonic acid. They also showed that LTA4 is converted to LXA4 by platelets and suggested that the 1 5-LO activity of platelets may be involved in this enzymatic conversion (16) . Here, we report that simultaneous activation of PMNs and platelets by receptor-mediated agonists leads to the formation ofboth LXA4 and LXB4 and that LTA4 is transformed by platelets to LXA4, LXB4, and the recently identified 7-cis-1 I-trans-LXA4 (17) . In addition, evidence is presented for the role of the platelet 1 2-LO and its w-6-oxygenase activity in converting LTA4 to lipoxins. Glossary ASA acetylsalicylic acid Esculetin 6,7-dihydroxycoumarin GC gas liquid chromatography 12-HETE 12S-hydroxy-5,8, 14-cis-10-trans-eicosatetraenoic acid 15 -HETE 1 5S-hydroxy-5,8,1 l-cis-13-trans-eicosatetraenoic acid HMDS hexamethyldisilazane HPETE hydroperoxyeicosatetraenoic acid LO lipoxygenase Lipoxin A4, (LXA4) 5S,6R, 1 5S-trihydroxy-7,9, 13-trans-11-cis-eicosatetraenoic acid Lipoxin B4, (LXB4) 5S, 14R, 1 5S-trihydroxy-6, 10,12-trans-8-cis-eicosatetraenoic acid 7-cis-1I-trans-LXA4 5S,6R, I 5S-trihydroxy-9, 1 1,13-trans-7-cis-eicosatetraenoic acid LTB4, leukotriene B4 5S, 12R-dihydroxy-6, 14-cis-8, 1 (Milford, MA) . Pyridine, hexamethyldisilazane (HMDS) and trimethylchlorosilane (TMCS) were from Pierce Chemical Co. (Rockford, IL), and diazomethane was prepared from N-methyl-V-nitro-N-nitroguanidine purchased from Aldrich Chemical Co. (Milwaukee, WI). Synthetic 7-cis-1 -trans-LXA4 was from Dr. K. C. Nicolaou, University of Pennsylvania (Philadelphia, PA). Synthetic LTA4-methyl ester, LXA4, LXB4, and esculetin (6,7-dihydroxycoumarin) were from Biomol Research Laboratories, Inc. (Philadelphia, PA). Other eicosanoids used as reference materials were prepared as described (7) ; these included 11- Preparation of human PMN and platelet suspensions. For each experiment, venous blood (-100-120 ml) was drawn from healthy volunteers who had not taken aspirin or other medications for at least 7 d. PMN and platelet suspensions were prepared (14, 19, 20) from the same heparinized blood directly after venipuncture. Platelet-rich plasma was removed after centrifugation at 160 g for 15 min at room temperature. Washed platelet suspensions were prepared (14, 20) , enumerated using a Coulter counter (model ZF; Coulter Electronics, Inc., Hialeah, FL) and suspended in PBS containing 0.1% albumin. In parallel, PMNs were isolated by dextran sedimentation of the remaining blood followed by Ficoll-Hypaque gradient centrifugation (19) . The red cells were removed by hypotonic lysis followed by centrifugation, and the isolated PMNs were suspended in Dulbecco's phosphate-buffered saline, pH 7.4. These suspensions contained 98±1% PMNs as determined by light microscopy before coincubation with isolated platelets. The integrity of cells in suspension was monitored both before and during incubation conditions by determining their ability to exclude trypan blue. Under all experimental conditions, < 3% of the PMNs in suspension were permeable to trypan blue. Cell-free 100,000 g supernatants of platelet lysates and PMN lysates were prepared (20) . Briefly, freshly isolated cell suspensions were rapidly frozen in a dry ice/acetone bath and thawed to room temperature. This sequence was repeated three times followed by centrifugation at 100,000 g for 60 min at 10°C. All incubations with 100,000 g supernatants were performed directly after centrifugation.
Incubation conditions. PMNs (3.5 X 107 cells) were coincubated with autologous platelets at a ratio of 1:10 (PMN/platelet) in PBS (I ml). After 5 min at 37°C, stimuli were added, which included either thrombin (0.1 U/ml) and FMLP (lO-' M), each added separately to individual cell populations, or cells incubated alone in the absence of stimuli. In coincubation experiments, platelets were treated with indomethacin (100 MM) for 20 min at 37°C before coincubations. In experiments with LTA4 and intact platelets, cells (1.5 X I09platelets/ml) were incubated 5 min at 37°C in PBS (I ml) containing 0.1% albumin before addition of either LTA4 (30 MM) alone or LTA4 (30 MM) and stimuli (either ionophore A23187; 0.1 IMM or thrombin; I U/ml). In these experiments platelets were treated with either ASA (100 MM), esculetin (100 MM), or indomethacin (100 MM) for 20 min at 37°C before incubation with LTA4 and ionophore (0.1 MM).
Analysis of eicosanoids. Incubations were terminated by addition of cold ethanol (2 vol) containing PGB2 as internal standard. The suspensions were placed at 4°C for a minimum of 30 min followed by centrifugation. Supernatants were removed and the remaining pellets were resuspended in MeOH (2 vol). This was repeated twice, and the resulting EtOH-and MeOH-containing supernatants were pooled and taken to dryness by rotoevaporation (17, 21) . Materials were resus-pended in MeOH/H20 (1:45 vol/vol) by vortexing in a round-bottom flask (-1-2 min) and transferred into a syringe followed by acidification to pH 3.5. Samples from each incubation were rapidly loaded into cartridges (C18 Sep-Paks), washed with H20 and eluted with hexane and methyl formate. Materials eluted in the methyl formate fractions were concentrated under argon and examined for ultraviolet-absorbing materials before injection into a RP-HPLC system, which consisted of dual-pump gradient HPLC (LKB Instruments, Bromma, Sweden) equipped with an Ultrasphere-ODS (4.6 mm X 25 cm) column (Beckman Instruments, Inc., Fullerton, CA), injector, and solvent controller (LKB Instruments). The column was eluted with a gradient consisting of MeOH/H20/acetic acid (65:35:0.01) as phase one (to-20 min), a linear gradient with MeOH/acetic acid (99.99:0.01) as phase two (20-50 min) and a flow rate of 1.0 ml/min. This HPLC system was equipped with a photodiode array rapid spectral detector linked to an AT&T PC6300, and post-HPLC run analyses were performed utilizing a 2146-002 Wavescan program (LKB Instruments) and a chromatography data system (3000 series; Nelson Analytical, Paramus, NJ). LO products were quantitated from stored ultraviolet spectral data after RP-HPLC where baselines were achieved by computer-aided manipulations (21) . The post-HPLC recovery of PGB2 was 69±6% (n = 7 with 25 determinations; mean±SE). Ultraviolet spectra not recorded online during HPLC were recorded with a spectrophotometer (model 8452; Hewlett-Packard Co., Palo Alto, CA). Levels of significance, P. of the differences between platelets treated with inhibitors and transformation in those incubated in their absence were calculated using Student's t test.
After HPLC, collected material was treated with diazomethane and converted to trimethylsilyl derivative by exposure to hexamethyldisilazane and trimethylchlorosilane in pyridine (7) . GC-MS was performed with a Hewlett-Packard 5988A MS equipped with an HP 59970A workstation, software and 5890 GC. A fused silica capillary SE-30 (Supelco, Inc., Bellefonte, PA) column 2-4004, 30 m, 0.25 mm i.d., 0.25 AM df was employed with a temperature program. The splitless on time was 0.90; initial temperature was 1 50°C (1 min), followed by 230°C (4 min), 240°C (8 min) and 245°C (12.0 min) with a 12.0min solvent delay time.
Results
FMLP is a potent PMN-directed stimulus, whereas thrombin exerts its primary actions on platelets (22, 23) . To further probe interactions between human PMNs and platelets, thrombin (0.1 U/ml) and FMLP (lO-' M) were added simultaneously to coincubations of platelets-PMNs (10:1) and the products generated were characterized. Analysis of methyl formate fractions by RP-HPLC revealed the presence of strongly absorbing materials when stored spectral data was recalled at 300 nm (Fig. 1) . The presence of these chromophores suggested that conjugated tetraene-containing products were generated (6) (7) (8) . Materials beneath the four peaks in Fig.  1 gave retention times identical to those of synthetic LXA4, LXB4, and their respective all-trans-isomers. In this RP-HPLC system 8-trans-LXB4 and 14S-8-trans-LXB4 coelute, as do 1 1trans-LXA4 and 6S-1 l-trans-LXA4 (21) . These products were not further resolved in the present studies and are denoted as trans-A and trans-B in the HPLC profiles.
Coincubations of platelets and PMNs without exposure to the combination of FMLP and thrombin did not generate these products. In addition, neither platelets incubated with thrombin alone nor PMNs incubated with either FMLP or thrombin alone generated detectable levels of these products (Table I) . To determine if the platelet cyclooxygenase was involved in their formation, isolated platelets were treated with indomethacin (100 AM) and washed before their coincubation with PMNs. Treatment with indomethacin did not result in a statistically significant reduction in the formation of the lipoxins (Table I) . Human PMN-derived eicosanoids can be transformed by platelets during cell-cell interactions (14, 24) . In particular, LTA4 has been shown to undergo transcellular metabolism in that it can be released from activated cells and enzymatically transformed to leukotrienes by a second cell type (25, 26) . To determine if this PMN-derived product was involved in the formation of lipoxins during PMN-platelet interactions, isolated platelets were incubated with LTA4 and the products formed were analyzed. After RP-HPLC, a similar profile of products was obtained as in the case of coincubations (Figs. 1 and 2). When the stored spectral data were recalled at 300 nm, several prominent peaks displaying strong absorbance at 300 nm were revealed (Fig. 2 , lower panel). An isogram plot of the spectral data (240-330 nm; upper panel, Fig. 2 ) showed that each of the products separated by RP-HPLC carried a conjugated tetraene chromophore. Although the RP-HPLC profiles obtained from these incubations (cf. Figs. 1 and 2) were similar, they were not identical. Here, small amounts of material in Fig. 2 coeluted with synthetic LXB4. In addition, a tetraenecontaining product that coeluted with 7-cis-1 -trans-LXA4 (17) was formed ( Fig. 2 ). Materials beneath the other three peaks coeluted with trans-B, trans-A, and LXA4.
To further substantiate the identity of the product that was generated from LTA4 by human platelets, the material that gave the retention time of LXA4 was collected after HPLC and pooled from several incubations. The pooled samples were treated with diazomethane and converted to the trimethylsilyl derivative for analysis by GC/MS. This material eluted as a broad peak on GC with an equivalent chain length corresponding to 24.0-24.1. Its mass spectrum ( Fig. 3 ) gave prominent ions at m/e 203 (base peak), 171, and 173 with weaker ions observed at m/e 289, 379, 492, and 582 (M). These ions and C-value are identical to those reported for both the leukocyte-derived and synthetic LXA4 (6, 7) .
The conversion of LTA4 to lipoxins was examined next with platelets incubated in the presence or absence of stimuli and with cells treated with inhibitors (Table II) . Exposure of platelets to either thrombin or ionophore enhanced the conversion of LTA4 to lipoxins. In the case of ionophore, -3.5% of the added LTA4 was recovered as lipoxins. Esculetin, which inhibits the conversion of AA by the platelet 12-LO (27), completely inhibited the conversion of LTA4 to lipoxins. In contrast, prior treatment of the cells with either ASA or indomethacin did not significantly block the formation of lipoxins.
Since human PMNs possess a 15-LO, it is possible the LTA4 could be converted by this enzyme to a 15-hydroperoxy-derivative. Formation of this intermediate from LTA4 could account for the formation of lipoxins (6) (7) (8) . To test this hypothesis, PMNs (30 X 106 cells/ml) were incubated with either LTA4 (30 ,uM) or LTA4 with A23187 (2.5 ,uM). In neither case did PMNs generate lipoxins from exogenous LTA4 (n = 3 different donors). Dose response studies with LTA4 (0.1, 1, 10, 50, and 100 ,uM LTA4) incubated with PMNs (20 min, 37°C) were also negative for lipoxin production from LTA4 (n = 2). Together these findings suggest that LTA4 is not converted to the 5(6)-epoxytetraene upon exposure to human PMNs.
In addition to 12-LO, human platelets also exhibit 1 5-LO activity (28) , which may be involved in the conversion of LTA4 to lipoxins. To examine further the conversion of LTA4 (20) . Incubation of LTA4 with the 100,000 g supernatant of platelets led to the formation of lipoxins ( Fig. 4 A) . The profile of products was similar to that observed with LTA4 and platelets (Fig. 2) . The isolated platelet-derived I100,000 g supernatants were devoid of 15-LO, as evidenced by the finding that AA was converted solely to 12-HETE and 15-HETE was not detected (Fig. 4 B) . Similar experiments were performed with I100,000 g supernatants prepared from isolated PMNs lysed by freeze thawing. In these experiments, LTA4 was converted to LTB4 ( Fig. 4 C) , and neither the woxidation products of LTB4 nor lipoxins were detected.
Activation of human platelets with thrombin results in a rise in intracellular free Ca"+, which may play a role in 1 activity in these cells (23, 29). Therefore, the role of Ca2l was assessed in the transformation ofLTA4 to lipoxins. Addition of EGTA (5 mM) significantly inhibited the transformation of LTA4 to LXA4. In contrast, inhibition of-7-cis-1 I -trans-LXA4 was not statistically significant (Table III) . Formation of 12-HETE from AA in these experiments was inhibited only 26% in the presence of EGTA (5 mM). When these supernatants were treated with esculetin, formation of lipoxins from LTA4 was completely inhibited (Table III) .
Discussion
In this paper we report the formation of lipoxins during coincubation of human PMNs and platelets. Their formation was initiated by exposure to both the chemotactic peptide FMLP and thrombin ( Fig. 1) . FMLP stimulates the release and oxygenation of AA in PMNs by receptor-mediated mechanisms (22, 30) , while thrombin stimulates the release and oxygenation of AA in platelets (23). Neither stimulus alone provoked the formation of lipoxins (Table I, Fig. 1 ), indicating that activation of both cell types was required for the formation of lipoxins. Previous results have suggested that lipoxins can be generated by cell-cell interaction (6, 7) . The present findings document for the first time that lipoxins can be generated by receptor-mediated activation of two cell types without addition of exogenous substrates. In addition, they both confirm and extend the findings of Edenius et al. with ionophore stimulated mixed platelet/granulocyte suspensions (16). Granulocytes isolated from eosinophilic donors generate LXA4 but not LXB4 when challenged with the ionophore A23187 (31) . Human PMNs generate small amounts of both LXA4 and LXB4 from endogenous sources in response to A23 187, which are enhanced upon addition of 1 5-HETE (21) . Lipoxins are also generated from AA by porcine leukocytes (32) , mastocytoma cells (33) , and bovine leukocytes (9) . Although the results of these studies document the production of lipoxins from AA, the biosynthetic route(s) involved in their formation from endogenous sources remain to be fully elucidated.
In the case of human PMNs, cells incubated with FMLP alone did not generate detectable levels of lipoxins (Table I) . When exposed, however, to FMLP and 1 5-HETE, they generate both LXA4 and LXB4 (7) . Along these lines, 1 5-HETE, a major product of AA metabolism in a variety of cell types (reviewed in reference 2), is rapidly transformed to lipoxins by activated human PMNs. During this event an inverse relationship is observed between leukotriene and lipoxin formation (21) . In this biosynthetic route, 15-HETE is converted to a Figure 4 . RP-HPLC profiles of products generated by cell-free (100,000 g) supernatants of platelet and PMN lysates. Isolated platelet suspensions (1 X 109/ml) were lysed by freeze-thawing and centrifuged for 60 min at 100,000 g. The cell-free 100,000 g supernatants were incubated with either LTA4 (50 MM) or AA (30 MM) for 20 min at 370C. (A) RP-HPLC profile of products generated from LTA4. (B) RP-HPLC profile obtained after incubation with AA. (C) Isolated PMNs (30 x 106 cells/0.5 ml) were lysed by freeze-thawing and centrifuged for 60 min at 100,000 g. The 100,000 g supernatants were incubated with LTA4 (50 AM) for 20 min at 370C. Esculetin treated 3 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 * Platelets (1.2 X 109 cells/ml) were lysed by freeze-thawing and 100,000 g supernatants were prepared as in Fig. 4 , A and B. Supernatants were incubated in PBS (0.5 ml) containing 0.1% albumin and exposed to either EGTA (5 mM) or esculetin (100 uM) for 20 min at 370C followed by addition of LTA4 (50 uM) for 20 min at 370C. Results are expressed in ng/l ml; mean±SE. t P < 0.02. (14, 15, 24) . In particular, LTA4, an intermediate in the formation of leukotrienes within its cell of origin, can also be released and transformed by a second cell type (24) (25) (26) . When LTA4 was added to platelets, several products that displayed conjugated tetraene chromophores were resolved (Fig. 2) , which coeluted with LXA4, the trans-A isomers of LXA4, 7-cis-1 -trans-LXA4 and the trans-B-isomers of LXB4. In these incubations LXB4 was formed in small amounts and 7-cis-1 -trans-LXA4, which was recently isolated (17), was also formed. Further analysis of the platelet-derived product showed that it displayed the identical properties on GC-MS as those of both synthetic and leukocyte-derived LXA4 (cf. Fig. 3;  reference 7) . On the basis of these findings, we conclude that human platelets can transform LTA4 to LXA4. These observations extend those recently reported by Edenius et al. (16) and suggest that during receptor-mediated activation of PMNs and platelets incubated together, LTA4 generated by PMNs can be transformed to lipoxins by platelets. Transformation of LTA4 to lipoxins by platelets was further characterized employing inhibitors with both intact cells and cell-free (100,000 g) supernatants. Treatment of platelets with either cyclooxygenase or LO inhibitors showed a differential effect on their formation (Tables I and II) . Treatment of platelets with either ASA or indomethacin did not result in statistically significant inhibition of lipoxin formation. In contrast, esculetin completely blocked the transformation ofLTA4 to lipoxins (Table II ), suggesting that LTA4 is a substrate for lipoxygenation.
Although human platelets display 1 2-LO as their major LO pathway, an arachidonate 15-LO activity is observed (28) . Since LTA4 contains an available 1,4-cis-pentadiene, it was of interest to examine which platelet LO was responsible for the conversion of LTA4 to lipoxins. To this end, cell-free 100,000 g supernatants were prepared from both isolated platelets and PMNs. Supernatants prepared from platelets lysed by the freeze-thawing technique convert AA to 12-HETE without detectable levels of 15-HETE (20) . The present results confirm this observation, since addition of AA or 14C-labeled AA to platelet 100,000 g supernatant led to formation of only 12-HETE and 1 5-HETE was not observed (Fig. 4 B) . Aliquots of these same supernatants transformed LTA4 to lipoxins ( Fig. 4  A) , which was inhibited by esculetin (Table III) . Taken together these findings suggest a role for the platelet 12-LO or its w-6 oxygenation activity in the transformation of LTA4 to lipoxins.
In contrast, supernatants (100,000 g) obtained from PMN lysates transformed LTA4 to LTB4 (Fig. 4 ) and lipoxins were not detected. These results are consistent with the concept that the major route of LTA4 metabolism within intact PMNs is its enzymatic conversion to LTB4 by LTA4 hydrolase (34) . They do not, however, rule out the existence of other routes of metabolism for LTA4.
During the interaction of PMNs and platelets, several routes of lipoxin formation may be operative. For example, with intact platelets LTA4 may be a substrate for the 15-LO activity observed in these cells (28) , which can generate a 5(6)epoxytetraene to give lipoxins (16). Along these lines, we have found that LTA4 is indeed a substrate for the soybean 1 5-LO and is quantitatively transformed to its I 5-hydroperoxy-derivative (a 5(6)-epoxytetraene, unpublished observation). Although such a route of lipoxin biosynthesis is possible, several lines of evidence suggest a direct action of the platelet 1 2-LO on LTA4: (a) the finding that intact platelets as well as their supernatants (100,000 g) that display 12-LO activity transform LTA4 to lipoxins (Figs. 2-4) ; (b) the pattern oflipoxins formed in both cases was similar and 6S-LXA4 was not observed in these HPLC profiles (Figs. 2 and 3 ). If the 5(6)-epoxytetraene was an intermediate in the biosynthesis oflipoxins in platelets, some nonenzymatic hydrolysis of the 5(6)-epoxytetraene would be expected to give rise to small amounts of 6S-LXA4, which are found in incubations with activated human leukocytes and 15-HETE (7) ; and (c) previous results indicate that the human platelet 1 2-LO can act with high efficiency on substrates other than arachidonate, including both 15-HPETE and 5-HETE (14, 35, 36) .
Although transcellular metabolism of LTA4 and its transformation by 12-LO may account for the formation of LXA4, only small amounts of LXB4 were noted in incubations with platelets and LTA4, while LXB4 was found in a ratio of -2:1 (LXA4/LXB4) in profiles obtained from coincubations (Table  I ). In addition, platelets incubated with LTA4 also generated 7-cis-1 l-trans-LXA4 ( Figs. 2 and 4) . These observations suggest that the formation of LXB4 during PMN-platelet interactions may involve additional biosynthetic routes or that regulatory interactions between 12-LO and LTA4 required for LXB4 formation are disrupted in the cell-free system. Several routes of LXB4 formation have been documented (8, 10, 11) . Whether they play a role during PMN-platelet interactions or whether platelets simply serve as an additional source of AA for-utilization by PMNs (14) remains to be determined.
Ca2" plays an important role in the activation of the 5-LO in leukocytes (37) . In contrast, Ca2+ chelation with EGTA does not completely inhibit the conversion of AA by 12-LO prepared from subcellular fractions ofhuman platelets (29) . In the present study, addition of EGTA (5 mM) to supernatants (100,000 g) only partially reduced the formation of 12-HETE (reduced by 26%). The formation of LXA4 as well as the all-trans-LX isomers was inhibited 70-80% in the presence of EGTA (Table III) , while its effect on 7-cis-I l-trans-LXA4 formation was not statistically significant. Since the orientation of substrates within the active site of LO plays a critical role in the chirality and the ratio of the products generated (38) , these observations with EGTA treatment suggest a role for divalent cations in both the orientation and transformation of LTA4 to lipoxins. In addition, both thrombin and ionophore enhanced the transformation of LTA4 by platelets (Table II) .
The human platelet LO stereoselectively abstracts hydrogen from carbon-10 of AA, which initiates an insertion of molecular oxygen at carbon-12 to form 12-HPETE (4). Since an alcohol group at carbon-15 is present in LXA4 (6, 7) , it is possible that the platelet 12-LO initiates lipoxin formation from LTA4 by abstraction of hydrogen at carbon-1 3 of LTA4 and thus displays its w-6 oxygenase activity with LTA4 as substrate. Indeed, results with purified 12-LO from porcine leukocytes indicate that this enzyme can catalyze oxygenations at either w-6 or w-9 positions depending upon the substrate (39). It is also likely that the opening of the 5(6)-epoxide intermediate to give a 5S,6R configuration as in LXA4 is directed by the enzyme, since the 6S-isomer of LXA4 (6S-LXA4) was not formed in these incubations. The all-trans isomers of LXA4 and LXB4 can be formed upon isolation of lipoxins and by non-enzymatic hydrolysis of the 5(6)-epoxytetraene intermediate (7, 8) . Their appearance here can, in part, reflect the formation of a delocalized cation intermediate after oxygenation of LTA4 by the 12-LO. Formation of a similar structure (i.e., an enzyme-bound delocalized cation generated by proton transfer) has been proposed in the biosynthesis of LXA4 and LXB4 from a common intermediate (40) . However, 'the detailed mechanism as well as the role of cofactors involved in the transformation of LTA4 by platelets awaits further studies with purified human 1 2-LO.
The finding that platelets can generate biologically relevant levels of these products during coincubation with PMNs is of interest in view of their bioactions. For example, at submicromolar concentrations, lipoxins stimulate endothelial-dependent relaxation of aortic strips (41) . LXA4 also provokes vasodilation (in vivo) (42) (43) (44) and stimulates the formation of prostacyclin by human endothelial cells, albeit at higher concentrations (45). In addition to extracellular roles, LXA4 may also serve an intracellular function since it activates isolated protein kinase C (46) and selectively stimulates its 'y-subspecies (47).
Counterregulatory actions have been observed with lipoxins. In the nanomolar range, LXA4 can antagonize both the cellular and in vivo actions of leukotriene6D4 in renal microcirculation (48) . Prior exposure of glomerular mesangial cells to LXA4 blocks both the binding of leukotriene D4 to its receptor and the generation of inositol-triphosphate in mesangial cells which can produce LXA4 (48, 55) . Agonisf-antagonist responses are also observed with human leukocytes (49, 50).
LXA4 promotes chemotaxis of granulocytes (10-9 M), while recent results show that prior exposure of PMNs to LXA4 (10-'0 M) inhibits the chemotactic response to either LTB4 or FMLP. In these studies, LXA4 also blocked both PI hydrolysis and calcium mobilization in human PMNs (50) .
Although platelets can generate lipoxins ( Figs. 1-4) , these products do not stimulate platelet aggregation (41) . Their role(s), ifany, in platelet function remains to be determined. In summary, the present results demonstrate that incubation of PMNs and platelets with FMLP and thrombin leads to the formation of lipoxins by receptor-mediated mechanisms. Although FMLP acts primarily on PMNs, the actions of thrombin are not exclusively directed toward platelets. Thrombin is also reported to induce chemotaxis, aggregation (51) and degranulation (52) with human PMNs. In addition, thrombinstimulated platelets adhere to PMNs (53) and activated platelets can enhance the functional responses ofPMNs (54) . Thus, the present results add to the complex repertoire of events that occurs during PMN-platelet interactions and they also provide evidence for a novel biosynthetic route for the formation of lipoxins, namely the conversion of LTA4 by the platelet 12-LO. Moreover, they suggest that lipoxins can also be formed after initial oxygenation by the 5-LO and transcellular metabolism. Since lipoxins have been found to possess vasoactive functions (41) (42) (43) (44) (45) , their formation during the interaction of PMNs with platelets may have implications in the regulation of hemostasis, inflammation, and the interactions of these cells with the vessel wall.
